

DAFTAR PUSTAKA

- Ashurst, J, & Dawson, A, 2019, 'Klebsiella Pneumonia', Retrieved: May 10, 2019, from <https://www.ncbi.nlm.nih.gov/books/NBK519004/>
- Azmi, S, Aljunid, S, Maimaiti, N, Ali, A, Muhammad Nur, A, De Rosas-Valera, M, Encluna, J, Mohamed, R, Wibowo, B, Komaryani, K, & Roberts, C, 2016, 'Assessing the burden of pneumonia using administrative data from Malaysia, Indonesia, and the Philippines', *International Journal of Infectious Diseases*, vol 49, pp.87-93
- Barbagelata, E., Cillóniz, C., Dominedò, C., Torres, A., Nicolini, A., & Solidoro, P., 2020, 'Gender differences in community-acquired pneumonia'. *Minerva Medica*, 111(2)
- Bethesda, 2018, 'Pneumonia', Retrieved: May 10, 2019, from <https://www.nlm.nih.gov/health-topics/pneumonia>
- Caballero, J., & Rello, J., 2011, 'Combination antibiotic therapy for community-acquired pneumonia', *Annals of Intensive Care*, 1(1)
- CDC, 2017, 'Pneumococcal Disease | Clinical | *Streptococcus pneumoniae* | CDC', Retrieved: May 10, 2019, from <https://www.cdc.gov/pneumococcal/clinicians/streptococcus-pneumoniae.html>
- CDC, 2018, '*Pseudomonas aeruginosa* in Healthcare Settings | HAI | CDC', Retrieved: May 10, 2019, from <https://www.cdc.gov/hai/organisms/pseudomonas.html>
- CDC, 2018, 'What Exactly is Antibiotic Resistance?', Retrieved: May 10, 2019, from <https://www.cdc.gov/drugresistance/index.html>
- CDC, 2019, 'Preventing Infections During Chemotherapy', Retrieved: July 20, 2020, from <https://www.cdc.gov/cancer/dcpc/resources/features/preventinfections/index.html>
- Cherazard, R, Epstein, M, Doan, T, Salim, T, Bharti, S, & Smith, M, 2017, 'Antimicrobial Resistant *Streptococcus pneumoniae*'. *American Journal of Therapeutics*, vol 24(3), pp.e361-e369
- Cunha, B., 2006, 'The atypical pneumonias: clinical diagnosis and importance.' *Clinical Microbiology and Infection*, 12, pp.12-24
- De Alba I., & Amin A., 2014, 'Pneumonia readmissions: risk factors and implications', *Ochsner J.*, 14(4):649-654
- Dreshaj, Sh., Doda-Ejupi, T., Tolaj, IQ., Mustafa, A., Kabashi, S., Shala, N., Geca, Nj., Aliu, A., Daka, A., & Basha, N., 'Clinical role of Cefixime in community-acquired infections', *Prilozi*. 2011 ;32(2):143-155
- Finch, R., Pemberton, K., & Gildon, K., 1998, 'Pneumonia: The Impact of Risk Factors on the Outcome of Treatment with Meropenem and Ceftazidime', *Journal of Chemotherapy*, 10(1), pp.35-46
- Gamache, J., 2019, 'Bacterial Pneumonia: Practice Essentials, Background, Pathophysiology', Retrieved: May 10, 2019, from <https://emedicine.medscape.com/article/300157-overview>
- Garin, N., Genné, D., Carballo, S., Chuard, C., Eich, G., Hugli, O., Lamy, O., Nendaz, M., Petignat, P., Perneger, T., Rutschmann, O., Seravalli, L., Harbarth, S. dan Perrier, A., 2014, 'β-Lactam Monotherapy vs β-Lactam–Macrolide

- Combination Treatment in Moderately Severe Community-Acquired Pneumonia', *JAMA Internal Medicine*, 174(12), p.1894
- Henig, O., & Kaye, K. S., 2017, 'Bacterial Pneumonia in Older Adults', *Infectious Disease Clinics of North America*, 31(4), 689–713
- Hoare, Z., & Lim, W., 2006, 'Pneumonia: update on diagnosis and management', *British Medical Journal*, vol 332(7549), pp.1077-1079
- Horita, N., Otsuka, T., Haranaga, S., Namkoong, H., Miki, M., Miyashita, N., Higa, F., Takahashi, H., Yoshida, M., Kohno, S., & Kaneko, T., 2016, 'Beta-lactam plus macrolides or beta-lactam alone for community-acquired pneumonia: A systematic review and meta-analysis', *Respirology*, 21(7), pp.1193-1200
- Huang, J., Hooper, P., & Marrie, T., 2006. 'Factors Associated with Length of Stay in Hospital for Suspected Community-Acquired Pneumonia', *Canadian Respiratory Journal*, 13(6), pp.317-324
- Jain, V., & Bhardwaj, A., 2019, 'Pneumonia Pathology', Retrieved: May 10, 2019, from <https://www.ncbi.nlm.nih.gov/pubmed/30252372>
- Jang, J., & Ahn, J., 2020, 'Reasons and Risk Factors for Readmission Following Hospitalization for Community-acquired Pneumonia in South Korea', *Tuberculosis and Respiratory Diseases*, 83(2), p.147
- Jr., T., Milkovich, G., Tennenberg, A., Xiang, J., Khashab, M., & Zadeikis, N., 2004, 'Clinical implications of 750 mg, 5-day levofloxacin for the treatment of community-acquired pneumonia', *Current Medical Research and Opinion*, 20(9), pp.1473-1481
- Kemenkes RI, 2011, 'Modul Penggunaan Obat Rasional', pp.3-12
- King, P., 2012, '*Haemophilus influenzae* and the lung (Haemophilus and the lung)', *Clinical and Translational Medicine*, vol 1(1), pp.10
- Kufe, D., Holland, J., & Frei, E., 2003, 'Cancer Medicine 6', *Hamilton, Ont.*: BC Decker
- Mandell, L., & Read, R., 2010, 'Infections of the lower respiratory tract. Antibiotic and Chemotherapy', 9th ed, London, *Elsevier Health Sciences UK*, pp.574-588
- Marrie, T., & Huang, J., 2005, 'Low-risk patients admitted with community-acquired pneumonia' *The American Journal of Medicine*, 118(12), pp.1357-1363
- McDonald, J., 2014, 'Handbook Of Biological Statistics', 3rd ed, Baltimore: *Sparky House Publishing*, pp.77-85
- Menéndez, R., Cremades, M., Martínez-Moragón, E., Soler, J., Reyes, S., & Perpiñá, M., 2003, 'Duration of length of stay in pneumonia: influence of clinical factors and hospital type', *European Respiratory Journal*, 22(4), pp.643-648
- Metlay, J., Waterer, G., Long, A., Anzueto, A., Brozek, J., Crothers, K., Cooley, L., Dean, N., Fine, M., Flanders, S., Griffin, M., Metersky, M., Musher, D., Restrepo, M., & Whitney, C., 2019, 'Diagnosis and Treatment of Adults with Community-acquired Pneumonia. An Official Clinical Practice Guideline of the American Thoracic Society and Infectious Diseases Society of America', *American Journal of Respiratory and Critical Care Medicine*, 200(7), pp.e45-e67

- Mizgerd, J, 2008, 'Acute Lower Respiratory Tract Infection', *New England Journal of Medicine*, vol 358(7), pp.716-727
- Nie, W., Li, B., & Xiu, Q., 2014, ' β -Lactam/macrolide dual therapy versus β -lactam monotherapy for the treatment of community-acquired pneumonia in adults: a systematic review and meta-analysis', *Journal of Antimicrobial Chemotherapy*, 69(6), pp.1441-1446
- Noreddin, A., & Elkhatib, W., 2010, 'Levofloxacin in the treatment of community-acquired pneumonia'. *Expert Review of Anti-infective Therapy*, 8(5), pp.505-514
- O'Neill, J, 2014, 'Antimicrobial Resistance: Tackling a crisis for the health and wealth of nations', Retrieved May 13, 2019, from <https://amr-review.org/Publications.html>
- Parrow, N, Fleming, R, & Minnick, M, 2013, 'Sequestration and Scavenging of Iron in Infection', *Infection and Immunity*, vol 81(10), pp.3503-3514
- PDPI, 2003, 'Pneumonia Komuniti - Pedoman Diagnosis & Penatalaksanaan Di Indonesia', Jakarta, **Perhimpunan Dokter Paru Indonesia**. pp.6-8
- Peraturan Menteri Kesehatan Republik Indonesia Nomor 8 Tahun 2015 Tentang Program Pengendalian Resistensi Antimikroba Di Rumah Sakit
- Postma, D., van Werkhoven, C., van Elden, L., Thijsen, S., Hoepelman, A., Kluytmans, J., Boersma, W., Compajen, C., van der Wall, E., Prins, J., Oosterheert, J., & Bonten, M., 2015, 'Antibiotic Treatment Strategies for Community-Acquired Pneumonia in Adults', *New England Journal of Medicine*, 372(14), pp.1312-1323
- Prina, E., Ranzani, O., & Torres, A., 2015, 'Community-acquired pneumonia'. *The Lancet*, vol 386(9998), pp.1097-1108
- Ragle, B., Karginov, V., & Wardenburg, BJ., 2009, 'Prevention and Treatment of *Staphylococcus aureus* Pneumonia with a β -Cyclodextrin Derivative', *Antimicrobial Agents and Chemotherapy*, vol 54(1), pp.298-304
- Raz-Pasteur, A., Shasha, D., & Paul, M., 2015, 'Fluoroquinolones or macrolides alone versus combined with β -lactams for adults with community-acquired pneumonia: Systematic review and meta-analysis', *International Journal of Antimicrobial Agents*, 46(3), pp.242-248
- Sitompul, F., Radji, M., & Bahtiar, A., 2016, 'Evaluasi Penggunaan Antibiotik dengan Metode Gyssens pada Pasien Stroke Rawat Inap di RSUD Koja secara Retrospektif (Periode KJS dan BPJS)', *Jurnal Kefarmasian Indonesia*, vol 6(1), p.31
- Soepandi, PZ., Burhan, E., Nawas, A., Giriputro, S., Isbaniah, F., Agustin, H., & Handayani, D., 2014, 'Pneumonia Komuniti - Pedoman Diagnosis & Penatalaksanaan Di Indonesia', 2nd ed, Jakarta, **Badan Penerbit FKUI**, pp.8-35

- Tristram, S., Jacobs, M., & Appelbaum, P., 2007, 'Antimicrobial Resistance in *Haemophilus influenzae*', *Clinical Microbiology Reviews*, vol 20(2), pp.368-389
- Versporten, A., Zarb, P., Caniaux, I., Gros, M., Drapier, N., Miller, M., Jarlier, V., Nathwani, D., & Goossens, H, 2018, 'Antimicrobial consumption and resistance in adult hospital inpatients in 53 countries: results of an internet-based global point prevalence survey', *Lancet Glob Health* 2018, vol 6, pp.e619–29
- Welte, T., & Köhnlein, T., 2009, 'Global and Local Epidemiology of Community-Acquired Pneumonia: The Experience of the CAPNETZ Network', *Seminars in Respiratory and Critical Care Medicine*, vol 30(02), pp.127-135
- WHO, 2007, 'Epidemic-prone & pandemic-prone acute respiratory diseases: Infection prevention & control in health-care facilities', Retrieved: May 10, 2019, from https://www.who.int/csr/resources/publications/WHO_CDS_EPR_2007_8/en/
- Wiemken, T., Peyrani, P., & Ramirez, J., 2012, 'Global Changes in the Epidemiology of Community-Acquired Pneumonia', *Seminars in Respiratory and Critical Care Medicine*, vol 33(03), pp.213-219
- Wong, J., & Evans, S., 2017, 'Bacterial Pneumonia in Patients with Cancer', *Clinics in Chest Medicine*, 38(2), pp.263-277
- Zilberberg, M., Nathanson, B., Sulham, K., Fan, W., & Shorr, A., 2017, '30-day readmission, antibiotics costs and costs of delay to adequate treatment of Enterobacteriaceae UTI, pneumonia, and sepsis: a retrospective cohort study', *Antimicrobial Resistance & Infection Control*, vol 6(1), pp.2-5
- Zilberberg, M., Shorr, A., Micek, S., Mody, S., & Kollef, M., 2008, 'Antimicrobial Therapy Escalation and Hospital Mortality Among Patients With Health-Care-Associated Pneumonia', *Chest*, vol 134(5), pp.963-9688